Please Wait.....
Report
MEA Lung Cancer Diagnostics Market - Industry Trends and Forecast to 2030
Market Report I 2022-11-01 I 248 Pages I Data Bridge Market Research
The Middle East and Africa lung cancer diagnostics market is projected to register a substantial CAGR of 9.7% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030
Market Segmentation:
Middle East and Africa Lung Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales), Country (South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, Rest of Middle East and Africa) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the Middle East and Africa lung cancer diagnostics market are:
- Rise in prevalence and incidence of lung cancer
- Increase in healthcare expenditure on cancer diagnosis and treatment
Market Players:
Some of the major players operating in the Middle East and Africa lung cancer diagnostics market are:
- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Abbott
- Quest Diagnostics Incorporated
- Bio-Rad Laboratories, Inc.
- Biocartis
- Danaher
- DiaSorin S.p.A
- LalPathLabs.com
- NanoString
- PerkinElmer Inc.
- QIAGEN
- Siemens Healthcare GmbH
TABLE OF CONTENTS
1 INTRODUCTION 52
1.1 OBJECTIVES OF THE STUDY 52
1.2 MARKET DEFINITION 52
1.3 OVERVIEW OF MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET 52
1.4 LIMITATIONS 54
1.5 MARKETS COVERED 54
2 MARKET SEGMENTATION 57
2.1 MARKETS COVERED 57
2.2 GEOGRAPHICAL SCOPE 58
2.3 YEARS CONSIDERED FOR THE STUDY 59
2.4 CURRENCY AND PRICING 59
2.5 DBMR TRIPOD DATA VALIDATION MODEL 60
2.6 MULTIVARIATE MODELLING 63
2.7 PRODUCT TYPE LIFELINE CURVE 63
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 65
2.9 DBMR MARKET POSITION GRID 66
2.10 MARKET TESTING TYPE COVERAGE GRID 68
2.11 VENDOR SHARE ANALYSIS 69
2.12 SECONDARY SOURCES 70
2.13 ASSUMPTIONS 70
3 EXECUTIVE SUMMARY 71
4 PREMIUM INSIGHTS 74
4.1 PORTER'S FIVE FORCES 75
4.2 PESTEL ANALYSIS 76
4.3 INDUSTRY INSIGHTS 77
5 EPIDERMIOLOGY 78
6 REGULATIONS 79
7 MARKET OVERVIEW 82
7.1 DRIVERS 84
7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION 84
7.1.2 INCREASING EARLY DIAGNOSIS OF LUNGS CANCER 85
7.1.3 INCREASING CASES OF LUNG CANCER 87
7.1.4 RISE IN PRODUCT APPROVALS 87
7.2 RESTRAINTS 89
7.2.1 POOR & LATE DIAGNOSIS OF LUNG CANCER 89
7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY 89
7.3 OPPORTUNITIES 91
7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 91
7.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 91
7.3.3 RISING AWARENESS OF LUNG CANCER 92
7.4 CHALLENGES 93
7.4.1 STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS 93
7.4.2 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 93
7.4.3 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 94
8 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 95
8.1 OVERVIEW 96
8.2 INSTRUMENTS 99
8.2.1 IMAGING INSTRUMENTS 100
8.2.1.1 CT SYSTEMS 100
8.2.1.2 ULTRASOUND SYSTEMS 100
8.2.1.3 MRI SYSTEMS 100
8.2.1.4 OTHERS 100
8.2.2 BIOPSY INSTRUMENTS 101
8.2.2.1 NEEDLE BIOPSY 101
8.2.2.2 ENDOSCOPIC BIOPSY 101
8.2.2.3 CORE BIOPSY 101
8.2.2.4 OTHERS 101
8.2.3 PATHOLOGY-BASED INSTRUMENTS 102
8.2.3.1 SLIDE STAINING SYSTEMS 102
8.2.3.2 TISSUE PROCESSING SYSTEMS 102
8.2.3.3 CELL PROCESSORS 102
8.2.3.4 PCR INSTRUMENTS 102
8.2.3.5 OTHERS PATHOLOGY-BASED INSTRUMENTS 102
8.3 CONSUMABLES AND ACCESSORIES 103
8.3.1 KITS 104
8.3.1.1 DNA POLYMERASE KITS 104
8.3.1.2 NUCLEIC ACID ISOLATION KITS 104
8.3.1.3 PCR KITS 104
8.3.1.4 OTHERS 104
8.3.2 REAGENTS 105
8.3.2.1 ASSAYS 105
8.3.2.2 BUFFERS 105
8.3.2.3 PRIMERS 105
8.3.2.4 OTHERS 105
8.3.3 PROBES 106
8.3.4 OTHER CONSUMABLES 106
9 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE 107
9.1 OVERVIEW 108
9.2 IMAGING TEST 111
9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 112
9.2.2 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 112
9.2.3 CHEST X-RAY 112
9.2.4 BONE SCAN 112
9.2.5 MRI 112
9.2.6 OTHERS 112
9.3 BIOMARKERS TEST 113
9.3.1 EGFR MUTATION TEST 114
9.3.2 KRAS MUTATION TEST 114
9.3.3 ALK TEST 114
9.3.4 HER2 TEST 114
9.3.5 OTHERS 115
9.4 BIOPSY 115
9.4.1 NEEDLE BIOPSY 116
9.4.2 BRONCHOSCOPY BIOPSY 116
9.4.3 CORE BIOPSY 116
9.4.4 OTHERS 116
9.5 BLOOD TEST 116
9.5.1 COMPLETE BLOOD COUNT (CBC) 117
9.5.2 BLOOD CHEMISTRY TESTS 117
9.5.3 OTHERS 117
9.6 OTHERS 118
10 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 119
10.1 OVERVIEW 120
10.2 NON-SMALL CELL LUNG CANCER 123
10.3 SMALL CELL LUNG CANCER 124
11 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY END USER 125
11.1 OVERVIEW 126
11.2 HOSPITAL 129
11.3 ASSOCIATED LABS 129
11.4 INDEPENDENT DIAGNOSTIC LABORATORIES 130
11.5 DIAGNOSTIC IMAGING CENTERS 131
11.6 CANCER RESEARCH INSTITUTES 131
11.7 OTHERS 132
12 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 133
12.1 OVERVIEW 134
12.2 DIRECT TENDER 137
12.3 RETAIL SALES 138
13 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY REGION 139
13.1 MIDDLE EAST AND AFRICA 140
13.1.1 SOUTH AFRICA 150
13.1.2 EGYPT 155
13.1.3 SAUDI ARABIA 160
13.1.4 U.A.E. 165
13.1.5 KUWAIT 170
13.1.6 OMAN 175
13.1.7 BAHRAIN 180
13.1.8 QATAR 185
13.1.9 REST OF MIDDLE EAST AND AFRICA 190
14 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 191
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 191
15 SWOT ANALYSIS 192
16 COMPANY PROFILE 193
16.1 F. HOFFMANN-LA ROCHE LTD. (2022) 193
16.1.1 COMPANY SNAPSHOT 193
16.1.2 REVENUE ANALYSIS 193
16.1.3 COMPANY SHARE ANALYSIS 194
16.1.4 PRODUCT PORTFOLIO 194
16.1.5 RECENT DEVELOPMENTS 194
16.2 THERMO FISHER SCIENTIFIC INC. (2022) 195
16.2.1 COMPANY SNAPSHOT 195
16.2.2 REVENUE ANALYSIS 195
16.2.3 COMPANY SHARE ANALYSIS 196
16.2.4 PRODUCT PORTFOLIO 196
16.2.5 RECENT DEVELOPMENTS 196
16.3 ABBOTT (2022) 197
16.3.1 COMPANY SNAPSHOT 197
16.3.2 REVENUE ANALYSIS 197
16.3.3 COMPANY SHARE ANALYSIS 198
16.3.4 PRODUCT PORTFOLIO 198
16.3.5 RECENT DEVELOPMENTS 198
16.4 QUEST DIAGNOSTICS INCORPORATED (2022) 199
16.4.1 COMPANY SNAPSHOT 199
16.4.2 REVENUE ANALYSIS 199
16.4.3 COMPANY SHARE ANALYSIS 200
16.4.4 PRODUCT PORTFOLIO 200
16.4.5 RECENT DEVELOPMENTS 202
16.5 BIODESIX (2022) 203
16.5.1 COMPANY PROFILE 203
16.5.2 REVENUE ANALYSIS 203
16.5.3 COMPANY SHARE ANALYSIS 204
16.5.4 PRODUCT PORTFOLIO 204
16.5.5 RECENT DEVELOPMENTS 204
16.6 AMOY DIAGNOSTICS CO., LTD. (2022) 205
16.6.1 COMPANY SNAPSHOT 205
16.6.2 PRODUCT PORTFOLIO 205
16.6.3 RECENT DEVELOPMENTS 205
16.7 BIO-RAD LABORATORIES, INC. (2022) 206
16.7.1 COMPANY SNAPSHOT 206
16.7.2 REVENUE ANALYSIS 206
16.7.3 PRODUCT PORTFOLIO 207
16.7.4 RECENT DEVELOPMENTS 207
16.8 BIOCARTIS (2022) 208
16.8.1 COMPANY SNAPSHOT 208
16.8.2 REVENUE ANALYSIS 208
16.8.3 PRODUCT PORTFOLIO 209
16.8.4 RECENT DEVELOPMENTS 209
16.9 BODITECH MED INC. 210
16.9.1 COMPANY PROFILE 210
16.9.2 PRODUCT PORTFOLIO 210
16.9.3 RECENT DEVELOPMENTS 210
16.10 DANAHER (2022) 211
16.10.1 COMPANY SNAPSHOT 211
16.10.2 REVENUE ANALYSIS 211
16.10.3 PRODUCT PORTFOLIO 212
16.10.4 RECENT DEVELOPMENTS 212
16.11 DIASORIN S.P.A. (2022) 213
16.11.1 COMPANY SNAPSHOT 213
16.11.2 REVENUE ANALYSIS 213
16.11.3 PRODUCT PORTFOLIO 214
16.11.4 RECENT DEVELOPMENTS 214
16.12 EXACT SCIENCES UK, LTD. (SUBSIDIARY OF EXACT SCIENCE CORPORATION) (2022) 215
16.12.1 COMPANY SNAPSHOT 215
16.12.2 REVENUE ANALYSIS 215
16.12.3 PRODUCT PORTFOLIO 216
16.12.4 RECENT DEVELOPMENTS 216
16.13 20/20 GENE SYSTEMS 217
16.13.1 COMPANY PROFILE 217
16.13.2 PRODUCT PORTFOLIO 217
16.13.3 RECENT DEVELOPMENTS 217
16.14 GUARDANT HEALTH INC. 218
16.14.1 COMPANY PROFILE 218
16.14.2 PRODUCT PORTFOLIO 218
16.14.3 RECENT DEVELOPMENTS 218
16.15 INIVATA LTD. 219
16.15.1 COMPANY PROFILE 219
16.15.2 PRODUCT PORTFOLIO 219
16.15.3 RECENT DEVELOPMENTS 219
16.16 LALPATHLABS.COM (2022) 220
16.16.1 COMPANY SNAPSHOT 220
16.16.2 REVENUE ANALYSIS 220
16.16.3 PRODUCT PORTFOLIO 221
16.16.4 RECENT DEVELOPMENTS 222
16.17 LUNGLIFE AI, INC. (2022) 223
16.17.1 COMPANY SNAPSHOT 223
16.17.2 PRODUCT PORTFOLIO 223
16.17.3 RECENT DEVELOPMENTS 223
16.18 MEDGENOME 224
16.18.1 COMPANY SNAPSHOT 224
16.18.2 PRODUCT PORTFOLIO 224
16.18.3 RECENT DEVELOPMENTS 225
16.19 MYRIAD GENETICS, INC. 226
16.19.1 COMPANY SNAPSHOT 226
16.19.2 PRODUCT PORTFOLIO 226
16.19.3 RECENT DEVELOPMENTS 226
16.20 NEOGENOMICS LABORATORIES (2022) 227
16.20.1 COMPANY SNAPSHOT 227
16.20.2 REVENUE ANALYSIS 227
16.20.3 PRODUCT PORTFOLIO 228
16.20.4 RECENT DEVELOPMENTS 228
16.21 NANOSTRING (2022) 229
16.21.1 COMPANY SNAPSHOT 229
16.21.2 REVENUE ANALYSIS 229
16.21.3 PRODUCT PORTFOLIO 230
16.21.4 RECENT DEVELOPMENTS 230
16.22 NANOENTEK 231
16.22.1 COMPANY PROFILE 231
16.22.2 PRODUCT PORTFOLIO 231
16.22.3 RECENT DEVELOPMENTS 231
16.23 ONCOCYTE CORPORATION 232
16.23.1 COMPANY PROFILE 232
16.23.2 SERVICE PORTFOLIO 232
16.23.3 RECENT DEVELOPMENTS 232
16.24 PERKINELMER INC 233
16.24.1 COMPANY PROFILE 233
16.24.2 REVENUE ANALYSIS 233
16.24.3 PRODUCT PORTFOLIO 234
16.24.4 RECENT DEVELOPMENTS 234
16.25 PLEXBIO 235
16.25.1 COMPANY SNAPSHOT 235
16.25.2 PRODUCT PORTFOLIO 235
16.25.3 RECENT DEVELOPMENTS 235
16.26 QIAGEN 236
16.26.1 COMPANY SNAPSHOT 236
16.26.2 REVENUE ANALYSIS 236
16.26.3 PRODUCT PORTFOLIO 237
16.26.4 RECENT DEVELOPMENTS 237
16.27 SIEMENS HEALTHCARE GMBH 238
16.27.1 COMPANY SNAPSHOT 238
16.27.2 REVENUE ANALYSIS 238
16.27.3 PRODUCT PORTFOLIO 239
16.27.4 RECENT DEVELOPMENTS 239
16.28 VERACYTE, INC. (2022) 240
16.28.1 COMPANY SNAPSHOT 240
16.28.2 REVENUE ANALYSIS 240
16.28.3 PRODUCT PORTFOLIO 241
16.28.4 RECENT DEVELOPMENTS 241
16.29 VELA DIAGNOSTICS 242
16.29.1 COMPANY PROFILE 242
16.29.2 PRODUCT PORTFOLIO 242
16.29.3 RECENT DEVELOPMENTS 244
17 QUESTIONNAIRE 245
18 RELATED REPORTS 248
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security